Literature DB >> 12746281

Cardiac function in mice lacking the glucagon-like peptide-1 receptor.

Robert Gros1, Xiaomang You, Laurie L Baggio, M Golam Kabir, Al Muktafi Sadi, Imran N Mungrue, Thomas G Parker, Qingling Huang, Daniel J Drucker, Mansoor Husain.   

Abstract

Glucagon-like peptide-1 (GLP-1) acts via its G protein-coupled receptor (GLP-1R) to regulate blood glucose. Although the GLP-1R is widely expressed in peripheral tissues, including the heart, and exogenous GLP-1 administration increases heart rate and blood pressure in rodents, the physiological importance of GLP-1R action in the cardiovascular system remains unclear. We now show that 2-month-old mice with genetic deletion of the GLP-1R (GLP-1R(-/-)) exhibit reduced resting heart rate and elevated left ventricular (LV) end diastolic pressure compared with CD-1 wild-type controls. At the age of 5 months, echocardiography and histology demonstrate increased LV thickness in GLP-1R(-/-) mice. Although baseline hemodynamic parameters of GLP-1R(-/-) did not differ significantly from those of wild type, GLP-1R(-/-) mice displayed impaired LV contractility and diastolic function after insulin administration. The defective cardiovascular response to insulin was not attributable to a generalized defect in the stress response, because GLP-1R(-/-) mice responded appropriately to insulin with increased c-fos expression in the hypothalamus and increased circulating levels of glucagon and epinephrine. Furthermore, LV contractility after exogenous epinephrine infusion was also reduced in GLP-1R(-/-) mice. These findings provide new evidence implicating an essential role for GLP-1R in the control of murine cardiac structure and function in vivo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12746281     DOI: 10.1210/en.2003-0007

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  67 in total

Review 1.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

Review 2.  Heart failure and loss of metabolic control.

Authors:  Zhao V Wang; Dan L Li; Joseph A Hill
Journal:  J Cardiovasc Pharmacol       Date:  2014-04       Impact factor: 3.105

3.  Cardioprotective GLP-1 metabolite prevents ischemic cardiac injury by inhibiting mitochondrial trifunctional protein-α.

Authors:  M Ahsan Siraj; Dhanwantee Mundil; Sanja Beca; Abdul Momen; Eric A Shikatani; Talat Afroze; Xuetao Sun; Ying Liu; Siavash Ghaffari; Warren Lee; Michael B Wheeler; Gordon Keller; Peter Backx; Mansoor Husain
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

4.  Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats.

Authors:  Annayya R Aroor; James R Sowers; Shawn B Bender; Ravi Nistala; Mona Garro; Irina Mugerfeld; Melvin R Hayden; Megan S Johnson; Muhammad Salam; Adam Whaley-Connell; Vincent G Demarco
Journal:  Endocrinology       Date:  2013-05-07       Impact factor: 4.736

Review 5.  Glucagon-like peptide-1 and its cardiovascular effects.

Authors:  Kyung-Sun Heo; Keigi Fujiwara; Jun-ichi Abe
Journal:  Curr Atheroscler Rep       Date:  2012-10       Impact factor: 5.113

Review 6.  The incretin system and cardiometabolic disease.

Authors:  Paul E Szmitko; Lawrence A Leiter; Subodh Verma
Journal:  Can J Cardiol       Date:  2010-02       Impact factor: 5.223

Review 7.  Type 2 diabetes mellitus and hypertension: an update.

Authors:  Guido Lastra; Sofia Syed; L Romayne Kurukulasuriya; Camila Manrique; James R Sowers
Journal:  Endocrinol Metab Clin North Am       Date:  2013-12-12       Impact factor: 4.741

Review 8.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

9.  The role of incretins in cardiovascular control.

Authors:  Derek D Mafong; Robert R Henry
Journal:  Curr Hypertens Rep       Date:  2009-02       Impact factor: 5.369

10.  Treatment of patients with diabetes with GLP-1 analogues or DPP-4- inhibitors: a hot topic for cardiologists?

Authors:  Thomas Jax
Journal:  Clin Res Cardiol       Date:  2008-10-13       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.